Olaparib for BRCA-mutated advanced ovarian cancer

Article Type

Article

Changed

Fri, 01/04/2019 - 11:11

Display Headline

Olaparib for BRCA-mutated advanced ovarian cancer

Author(s)

Edited Jame Abraham

Report Prepared Jane De Lartigue

Epithelial ovarian cancer is the leading cause of death from gynecologic cancer in the United States and the fifth most common cause of cancer-related mortality. Treatment options, particularly for tumors with mutations in the breast cancer susceptibility genes, BRCA1 and BRCA2, are currently limited, and significant research has focused on the development of novel therapies. Inhibitors of poly(ADP)ribose polymerase (PARP), which specifically target BRCA-mutant cancer cells by exploiting the defective DNA repair pathways inherent in these tumors, have proven particularly promising, though clinical development has not been without challenges. Development of olaparib was halted in 2011 following disappointing clinical trial results, but the manufacturer resurrected the drug following retrospective analyses in patients with BRCA1/2 mutations.

Click on the PDF icon at the top of this introduction to read the full article.

Article PDF

JCSO_june_206_DeLartigue_CT.pdf

Issue

The Journal of Community and Supportive Oncology - 13(6)

Publications

The Journal of Community and Supportive Oncology

MDedge Hematology and Oncology

Topics

Gynecologic Cancer

Page Number

206-208

Legacy Keywords

olaparib, Epithelial ovarian cancer, BRCA1, BRCA2, PARP inhibitors, BRCA-mutated,

Sections

Community Translations

Author(s)

Edited Jame Abraham

Report Prepared Jane De Lartigue

Author(s)

Edited Jame Abraham

Report Prepared Jane De Lartigue

Article PDF

JCSO_june_206_DeLartigue_CT.pdf

Article PDF

JCSO_june_206_DeLartigue_CT.pdf

Epithelial ovarian cancer is the leading cause of death from gynecologic cancer in the United States and the fifth most common cause of cancer-related mortality. Treatment options, particularly for tumors with mutations in the breast cancer susceptibility genes, BRCA1 and BRCA2, are currently limited, and significant research has focused on the development of novel therapies. Inhibitors of poly(ADP)ribose polymerase (PARP), which specifically target BRCA-mutant cancer cells by exploiting the defective DNA repair pathways inherent in these tumors, have proven particularly promising, though clinical development has not been without challenges. Development of olaparib was halted in 2011 following disappointing clinical trial results, but the manufacturer resurrected the drug following retrospective analyses in patients with BRCA1/2 mutations.

Click on the PDF icon at the top of this introduction to read the full article.

Epithelial ovarian cancer is the leading cause of death from gynecologic cancer in the United States and the fifth most common cause of cancer-related mortality. Treatment options, particularly for tumors with mutations in the breast cancer susceptibility genes, BRCA1 and BRCA2, are currently limited, and significant research has focused on the development of novel therapies. Inhibitors of poly(ADP)ribose polymerase (PARP), which specifically target BRCA-mutant cancer cells by exploiting the defective DNA repair pathways inherent in these tumors, have proven particularly promising, though clinical development has not been without challenges. Development of olaparib was halted in 2011 following disappointing clinical trial results, but the manufacturer resurrected the drug following retrospective analyses in patients with BRCA1/2 mutations.

Click on the PDF icon at the top of this introduction to read the full article.

Issue

The Journal of Community and Supportive Oncology - 13(6)

Issue

The Journal of Community and Supportive Oncology - 13(6)

Page Number

206-208

Page Number

206-208

Publications

The Journal of Community and Supportive Oncology

MDedge Hematology and Oncology